AndersonW.F. (1990). Why start a new journal on human gene therapy?. Hum Gene Ther., 1, 1–2.
2.
BryantL.M., ChristopherD.M., GilesA.R., et al. (2013). Lessons learned from the clinical development and market authorization of Glybera. Hum Gene Ther., 24, 55–64.
3.
FerreiraV., TwiskJ., KwikkersK., et al. (2013). Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPLS447X) in a phase II clinical trial of Lipoprotein Lipase deficiency (LPLD) gene therapy. Hum Gene Ther. [Epub ahead of print]; DOI: 10.1089/hum-2013-169.
4.
RipJ., NiermanM.C., SiertsJ.A., et al. (2005). Gene therapy for lipoprotein lipase deficiency: working toward clinical application. Hum Gene Ther., 16, 1276–1286.
5.
RossC.J.D., TwiskJ., MeulenbergJ.M., et al. (2004). Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPLS447X beneficial mutation. Hum Gene Ther., 15, 906–919.
6.
RossC.J.D., TwiskJ., BakkerA.C., et al. (2006). Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation. Hum Gene Ther., 17, 487–499.
7.
WilsonJ.M. (2011). The birth of Human Gene Therapy Methods. Hum Gene Ther., 22, 1031–1032.
8.
WilsonJ.M. (2012). Moving to the clinic with gene therapy through our new journal expansion, Human Gene Therapy Clinical Development. Hum Gene Ther., 23, 1029–1030.
